Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04315701
Title A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California

skin squamous cell carcinoma



Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.